Antiparasitic chemotherapy: From genomes to mechanisms

Annual Review of Pharmacology and Toxicology

Volumn 54, Issue , 2014, Pages 71-94

  Horn, David ^a   Duraisingh, Manoj T ^b  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Antimicrobial; Chemical genomics; Drug resistance; High throughput; Plasmodium falciparum; Trypanosoma brucei

Indexed keywords

ANTIMALARIAL AGENT; ANTIPARASITIC AGENT; ARTEMISIN; ATOVAQUONE; ATOVAQUONE PLUS PROGUANIL; BENFLUMETOL; CHLOROQUINE; EFLORNITHINE; FEXINIDAZOLE; HALOFANTRINE; MEFLOQUINE; MELARSOPROL; METHOTREXATE; NIFURTIMOX; PENTAMIDINE; PIPERAQUINE; PRIMAQUINE; PROGUANIL; PYRIMETHAMINE; PYRIMETHAMINE PLUS SULFADOXINE; PYRONARIDINE; QUININE; SULFADOXINE; SURAMIN;

AFRICAN TRYPANOSOMIASIS; ANTIMALARIAL DRUG SUSCEPTIBILITY; CHEMOTHERAPY; CLINICAL TRIAL (TOPIC); DISEASE CONTROL; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; DRUG TRANSPORT; DRUG UPTAKE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE MAPPING; GENE SEQUENCE; GENETIC ASSOCIATION; GENOME; GENOMICS; HOST PARASITE INTERACTION; HUMAN; LEISHMANIA; MALARIA; METABOLISM; METABOLOMICS; MUTANT; NONHUMAN; PHENOTYPE; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; REVIEW; SCREENING; TECHNOLOGY; TOXOPLASMA GONDII; WHOLE CELL;

ANTIPARASITIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; DRUG RESISTANCE; GENOME, PROTOZOAN; GENOMICS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALARIA; MOLECULAR TARGETED THERAPY; PHENOTYPE; TRYPANOSOMIASIS;

EID: 84891890241     PISSN: 03621642     EISSN: 15454304     Source Type: Book Series    
DOI: 10.1146/annurev-pharmtox-011613-135915     Document Type: Review

References (158)

1. Maser P, Wittlin S, Rottmann M, Wenzler T, Kaiser M, Brun R. 2012. Antiparasitic agents: new drugs on the horizon. Curr. Opin. Pharmacol. 12:562-66
2. Miller LH, Baruch DI, Marsh K, Doumbo OK. 2002. The pathogenic basis of malaria. Nature 415:673-79
3. Stockwell BR. 2000. Chemical genetics: ligand-based discovery of gene function. Nat. Rev. Genet. 1:116-25
4. Besnard J, Ruda GF, Setola V, Abecassis K, Rodriguiz RM, et al. 2012. Automated design of ligands to polypharmacological profiles. Nature 492:215-20
5. Hopkins AL. 2008. Network pharmacology: the next paradigm in drug discovery. Nat. Chem. Biol. 4:682-90
6. Okell LC, Drakeley CJ, Bousema T, Whitty CJ, Ghani AC. 2008. Modelling the impact of artemisinin combination therapy and long-acting treatments on malaria transmission intensity. PLoS Med. 5:e226; discussion e226
7. Paddon CJ, Westfall PJ, Pitera DJ, Benjamin K, Fisher K, et al. 2013. High-level semi-synthetic production of the potent antimalarial artemisinin. Nature 496:528-32
8. Taylor TE, Wills BA, Kazembe P, Chisale M, Wirima JJ, et al. 1993. Rapid coma resolution with artemether in Malawian children with cerebral malaria. Lancet 341:661-62
9. Baird JK. 2004. Chloroquine resistance in Plasmodium vivax. Antimicrob. Agents Chemother. 48:4075-83
10. Hawkins VN, Auliff A, Prajapati SK, Rungsihirunrat K, Hapuarachchi HC, et al. 2008. Multiple origins of resistance-conferring mutations in Plasmodium vivax dihydrofolate reductase. Malar. J. 7:72
11. + regulation in the malaria parasite Plasmodium falciparum involves the cation ATPase PfATP4 and is a target of the spiroindolone antimalarials. Cell Host Microbe 13:227-37
12. Steverding D. 2010. The development of drugs for treatment of sleeping sickness: a historical review. Parasites Vectors 3:15
13. Wilkinson SR, Kelly JM. 2009. Trypanocidal drugs:mechanisms, resistance and new targets. Expert Rev. Mol. Med. 11:e31
14. Priotto G, Kasparian S, Mutombo W, Ngouama D, Ghorashian S, et al. 2009. Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial. Lancet 374:56-64
15. Simarro PP, Franco J, Diarra A, Postigo JA, Jannin J. 2012. Update on field use of the available drugs for the chemotherapy of human African trypanosomiasis. Parasitology 139:842-46
16. Kotthaus J, Schade D, Schwering U, Hungeling H, Muller-Fielitz H, et al. 2011. New prodrugs of the antiprotozoal drug pentamidine. Chem Med Chem 6:2233-42
17. Wenzler T, Boykin DW, Ismail MA, Hall JE, Tidwell RR, Brun R. 2009. New treatment option for second-stage African sleeping sickness: in vitro and in vivo efficacy of aza analogs of DB289. Antimicrob. Agents Chemother. 53:4185-92
18. Thuita JK, Wang MZ, Kagira JM, Denton CL, Paine MF, et al. 2012. Pharmacology of DB844, an orally active aza analogue of pafuramidine, in a monkey model of second stage human African trypanosomiasis. PLoS Negl. Trop. Dis. 6:e1734
19. Kaiser M, Bray MA, Cal M, Bourdin Trunz B, Torreele E, Brun R. 2011. Antitrypanosomal activity of fexinidazole, a new oral nitroimidazole drug candidate for treatment of sleeping sickness. Antimicrob. Agents Chemother. 55:5602-8
20. Jacobs RT, Nare B, Wring SA, Orr MD, Chen D, et al. 2011. SCYX-7158, an orally-active benzoxaborole for the treatment of stage 2 human African trypanosomiasis. PLoS Negl. Trop. Dis. 5:e1151
21. Fairhurst RM, Nayyar GM, Breman JG, Hallett R, Vennerstrom JL, et al. 2012. Artemisinin-resistant malaria: research challenges, opportunities, and public health implications. Am. J. Trop. Med. Hyg. 87:231-41
22. AlKadi HO. 2007. Antimalarial drug toxicity: a review. Chemotherapy 53:385-91
23. malERA Consult. Group Drugs. 2011. A research agenda for malaria eradication: drugs. PLoS Med. 8:e1000402
24. Salvidio E, Pannacciulli I, Tizianello A, Ajmar F. 1967. Nature of hemolytic crises and the fate of G6PD deficient, drug-damaged erythrocytes in Sardinians. N. Engl. J. Med. 276:1339-44
25. Bowman ZS, Oatis JE Jr, Whelan JL, Jollow DJ, McMillan DC. 2004. Primaquine-induced hemolytic anemia: susceptibility of normal versus glutathione-depleted rat erythrocytes to 5-hydroxyprimaquine. J. Pharmacol. Exp. Ther. 309:79-85
26. Iten M, Mett H, Evans A, Enyaru JC, Brun R, Kaminsky R. 1997. Alterations in ornithine decarboxylase characteristics account for tolerance of Trypanosoma brucei rhodesiense to D, L-α-difluoromethylornithine. Antimicrob. Agents Chemother. 41:1922-25
27. Kuepfer I, Schmid C, Allan M, Edielu A, Haary EP, et al. 2012. Safety and efficacy of the 10-day melarsoprol schedule for the treatment of second stage Rhodesiense sleeping sickness. PLoS Negl. Trop. Dis. 6:e1695
28. Damper D, Patton CL. 1976. Pentamidine transport and sensitivity in brucei-group trypanosomes. J. Protozool. 23:349-56
29. Frommel TO, Balber AE. 1987. Flow cytofluorimetric analysis of drug accumulation by multidrugresistant Trypanosoma brucei brucei and T. b. rhodesiense. Mol. Biochem. Parasitol. 26:183-91
30. Maser P, Luscher A, Kaminsky R. 2003. Drug transport and drug resistance in African trypanosomes. Drug Resist. Updates 6:281-90
31. Rollo IM, Williamson J. 1951. Acquired resistance to 'Melarsen', tryparsamide and amidines in pathogenic trypanosomes after treatment with 'Melarsen' alone. Nature 167:147-48
32. Maes L, Doua F, Hamers R. 1988. ELISA assay for melarsoprol. Bull. Soc. Pathol. Exot. Filiales 81:557-60
33. Duraisingh MT, Cowman AF. 2005. Contribution of the pfmdr1 gene to antimalarial drug-resistance. Acta Trop. 94:181-90
34. Ecker A, Lehane AM, Clain J, Fidock DA. 2012. PfCRT and its role in antimalarial drug resistance. Trends Parasitol. 28:504-14
35. Maser P, Sutterlin C, Kralli A, Kaminsky R. 1999. A nucleoside transporter from Trypanosoma brucei involved in drug resistance. Science 285:242-44
36. Stewart ML, Krishna S, Burchmore RJ, Brun R, de Koning HP, et al. 2005. Detection of arsenical drug resistance in Trypanosoma brucei with a simple fluorescence test. Lancet 366:486-87
37. Kapetanaki S, Varotsis C. 2001. Fourier transform infrared investigation of non-heme Fe(III) and Fe(II) decomposition of artemisinin and of a simplified trioxane alcohol. J. Med. Chem. 44:3150-56
38. Meshnick SR. 2002. Artemisinin: mechanisms of action, resistance and toxicity. Int. J. Parasitol. 32:1655-60
39. Wilkinson SR, Taylor MC, Horn D, Kelly JM, Cheeseman I. 2008. A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes. Proc. Natl. Acad. Sci. USA 105:5022-27
40. Wyllie S, Patterson S, Fairlamb AH. 2013. Assessing the essentiality of Leishmania donovani nitroreductase and its role in nitro drug activation. Antimicrob. Agents Chemother. 57:901-6
41. Manjunatha UH, Boshoff H, Dowd CS, Zhang L, Albert TJ, et al. 2006. Identification of a nitroimidazooxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. USA 103:431-36
42. Sokolova AY, Wyllie S, Patterson S, Oza SL, Read KD, Fairlamb AH. 2010. Cross-resistance to nitro drugs and implications for treatment of human African trypanosomiasis. Antimicrob. Agents Chemother. 54:2893-900
43. Reeder JC, Rieckmann KH, Genton B, Lorry K, Wines B, Cowman AF. 1996. Pointmutations in the dihydrofolate reductase and dihydropteroate synthetase genes and in vitro susceptibility to pyrimethamine and cycloguanil of Plasmodium falciparum isolates from Papua New Guinea. Am. J. Trop. Med. Hyg. 55:209-13
44. Triglia T, Wang P, Sims PF, Hyde JE, Cowman AF. 1998. Allelic exchange at the endogenous genomic locus in Plasmodium falciparum proves the role of dihydropteroate synthase in sulfadoxine-resistant malaria. EMBO J. 17:3807-15
45. Triglia T, Menting JG, Wilson C, Cowman AF. 1997. Mutations in dihydropteroate synthase are responsible for sulfone and sulfonamide resistance in Plasmodium falciparum. Proc. Natl. Acad. Sci. USA 94:13944-49
46. Srivastava IK, Vaidya AB. 1999. A mechanism for the synergistic antimalarial action of atovaquone and proguanil. Antimicrob. Agents Chemother. 43:1334-39
47. Edwards KJ, Jenkins TC, Neidle S. 1992. Crystal structure of a pentamidine-oligonucleotide complex: implications for DNA-binding properties. Biochemistry 31:7104-9
48. Shapiro TA, Englund PT. 1990. Selective cleavage of kinetoplast DNA minicircles promoted by antitrypanosomal drugs. Proc. Natl. Acad. Sci. USA 87:950-54
49. Schnaufer A. 2010. Evolution of dyskinetoplastic trypanosomes: How, and how often? Trends Parasitol. 26:557-58
50. Lanteri CA, Tidwell RR, Meshnick SR. 2008. The mitochondrion is a site of trypanocidal action of the aromatic diamidine DB75 in bloodstream forms of Trypanosoma brucei. Antimicrob. Agents Chemother. 52:875-82
51. Moreno SN. 1996. Pentamidine is an uncoupler of oxidative phosphorylation in rat liver mitochondria. Arch. Biochem. Biophys. 326:15-20
52. Mathis AM, Holman JL, Sturk LM, Ismail MA, Boykin DW, et al. 2006. Accumulation and intracellular distribution of antitrypanosomal diamidine compounds DB75 and DB820 in African trypanosomes. Antimicrob. Agents Chemother. 50:2185-91
53. Wilson WD, Tanious FA, Mathis A, Tevis D, Hall JE, Boykin DW. 2008. Antiparasitic compounds that target DNA. Biochimie 90:999-1014
54. Fairlamb AH, Henderson GB, Cerami A. 1989. Trypanothione is the primary target for arsenical drugs against African trypanosomes. Proc. Natl. Acad. Sci. USA 86:2607-11
55. Jacobs RT, Nare B, Phillips MA. 2011. State of the art in African trypanosome drug discovery. Curr. Top. Med. Chem. 11:1255-74
56. Frearson JA, Brand S, McElroy SP, Cleghorn LA, Smid O, et al. 2010. N-myristoyltransferase inhibitors as new leads to treat sleeping sickness. Nature 464:728-32
57. Gardner MJ, Hall N, Fung E, White O, Berriman M, et al. 2002. Genome sequence of the human malaria parasite Plasmodium falciparum. Nature 419:498-511
58. Berriman M, Ghedin E, Hertz-Fowler C, Blandin G, Renauld H, et al. 2005. The genome of the African trypanosome Trypanosoma brucei. Science 309:416-22
59. Mackey ZB, Koupparis K, Nishino M, McKerrow JH. 2011. High-throughput analysis of an RNAi library identifies novel kinase targets in Trypanosoma brucei. Chem. Biol. Drug Des. 78:454-63
60. Naula C, Parsons M, Mottram JC. 2005. Protein kinases as drug targets in trypanosomes and Leishmania. Biochim. Biophys. Acta 1754:151-59
61. de Koning HP, Gould MK, Sterk GJ, Tenor H, Kunz S, et al. 2012. Pharmacological validation of Trypanosoma brucei phosphodiesterases as novel drug targets. J. Infect. Dis. 206:229-37
62. Horn D. 2008. Histone deacetylases. Adv. Exp. Med. Biol. 625:81-86
63. McKerrow JH, Engel JC, Caffrey CR. 1999. Cysteine protease inhibitors as chemotherapy for parasitic infections. Bioorg. Med. Chem. 7:639-44
64. Nkemngu NJ, Rosenkranz V, Wink M, Steverding D. 2002. Antitrypanosomal activities of proteasome inhibitors. Antimicrob. Agents Chemother. 46:2038-40
65. Aguero F, Al-Lazikani B, Aslett M, Berriman M, Buckner FS, et al. 2008. Genomic-scale prioritization of drug targets: the TDR Targets database. Nat. Rev. Drug Discov. 7:900-7
66. Alsford S, Turner DJ, Obado SO, Sanchez-Flores A, Glover L, et al. 2011. High-throughput phenotyping using parallel sequencing of RNAinterference targets in the African trypanosome. Genome Res. 21:915-24
67. Wirtz E, Leal S, Ochatt C, Cross GA. 1999. A tightly regulated inducible expression system for conditional gene knock-outs and dominant-negative genetics in Trypanosoma brucei. Mol. Biochem. Parasitol. 99:89-101
68. Magarinos MP, Carmona SJ, Crowther GJ, Ralph SA, Roos DS, et al. 2012. TDR Targets: a chemogenomics resource for neglected diseases. Nucleic Acids Res. 40:D1118-27
69. Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL. 2007. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat. Rev. Drug Discov. 6:29-40
70. Militello KT, Refour P, Comeaux CA, Duraisingh MT. 2008. Antisense RNA and RNAi in protozoan parasites: Working hard or hardly working? Mol. Biochem. Parasitol. 157:117-26
71. Pino P, Sebastian S, Kim EA, Bush E, Brochet M, et al. 2012. A tetracycline-repressible transactivator system to study essential genes in malaria parasites. Cell Host Microbe 12:824-34
72. Dvorin JD, Martyn DC, Patel SD, Grimley JS, Collins CR, et al. 2010. A plant-like kinase in Plasmodium falciparum regulates parasite egress from erythrocytes. Science 328:910-12
73. Chong CR, Chen X, Shi L, Liu JO, Sullivan DJ Jr. 2006. Aclinical drug library screen identifies astemizole as an antimalarial agent. Nat. Chem. Biol. 2:415-16
74. Weisman JL, Liou AP, Shelat AA, Cohen FE, Guy RK, De Risi JL. 2006. Searching for new antimalarial therapeutics amongst known drugs. Chem. Biol. Drug Des. 67:409-16
75. Guiguemde WA, Shelat AA, Bouck D, Duffy S, Crowther GJ, et al. 2010. Chemical genetics of Plasmodium falciparum. Nature 465:311-15
76. Gamo FJ, Sanz LM, Vidal J, de Cozar C, Alvarez E, et al. 2010. Thousands of chemical starting points for antimalarial lead identification. Nature 465:305-10
77. Plouffe D, Brinker A, McNamara C, Henson K, Kato N, et al. 2008. In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen. Proc. Natl. Acad. Sci. USA 105:9059-64
78. Baniecki ML, Wirth DF, Clardy J. 2007. High-throughput Plasmodium falciparum growth assay for malaria drug discovery. Antimicrob. Agents Chemother. 51:716-23
79. Jensen K, Plichta D, Panagiotou G, Kouskoumvekaki I. 2012. Mapping the genome of Plasmodium falciparum on the drug-like chemical space reveals novel anti-malarial targets and potential drug leads. Mol. BioSyst. 8:1678-85
80. Brown LE, Chih-Chien Cheng K, Wei WG, Yuan P, Dai P, et al. 2011. Discovery of new antimalarial chemotypes through chemical methodology and library development. Proc. Natl. Acad. Sci. USA 108:6775-80
81. Mackey ZB, Baca AM, Mallari JP, Apsel B, Shelat A, et al. 2006. Discovery of trypanocidal compounds by whole cell HTS of Trypanosoma brucei. Chem. Biol. Drug Des. 67:355-63
82. Cong F, Cheung AK, Huang SA. 2012. Chemical genetics-based target identification in drug discovery. Annu. Rev. Pharmacol. Toxicol. 52:57-78
83. Terstappen GC, Schlupen C, Raggiaschi R, Gaviraghi G. 2007. Target deconvolution strategies in drug discovery. Nat. Rev. Drug Discov. 6:891-903
84. Walliker D, Quakyi IA, Wellems TE, McCutchan TF, Szarfman A, et al. 1987. Genetic analysis of the human malaria parasite Plasmodium falciparum. Science 236:1661-66
85. Su X, Kirkman LA, Fujioka H, Wellems TE. 1997. Complex polymorphisms in an approximately 330 kDa protein are linked to chloroquine-resistant P. falciparum in Southeast Asia and Africa. Cell 91:593-603
86. Sidhu AB, Verdier-Pinard D, Fidock DA. 2002. Chloroquine resistance in Plasmodium falciparum malaria parasites conferred by pfcrt mutations. Science 298:210-13
87. Ferdig MT, Cooper RA, Mu J, Deng B, Joy DA, et al. 2004. Dissecting the loci of low-level quinine resistance in malaria parasites. Mol. Microbiol. 52:985-97
88. Desai SA. 2012. Ion and nutrient uptake bymalaria parasite-infected erythrocytes. Cell Microbiol. 14:1003-9
89. Tait A, Morrison LJ, Duffy CW, Cooper A, Turner CM, Macleod A. 2011. Trypanosome genetics: populations, phenotypes and diversity. Vet. Parasitol. 181:61-68
90. Mu J, Duan J, Makova KD, Joy DA, Huynh CQ, et al. 2002. Chromosome-wide SNPs reveal an ancient origin for Plasmodium falciparum. Nature 418:323-26
91. Park DJ, Lukens AK, Neafsey DE, Schaffner SF, Chang HH, et al. 2012. Sequence-based association and selection scans identify drug resistance loci in the Plasmodium falciparum malaria parasite. Proc. Natl. Acad. Sci. USA 109:13052-57
92. Van Tyne D, Park DJ, Schaffner SF, Neafsey DE, Angelino E, et al. 2011. Identification and functional validation of the novel antimalarial resistance locus PF10-0355 in Plasmodium falciparum. PLoS Genet. 7:e1001383
93. Takala-Harrison S, Clark TG, Jacob CG, Cummings MP, Miotto O, et al. 2013. Genetic loci associated with delayed clearance of Plasmodium falciparum following artemisinin treatment in Southeast Asia. Proc. Natl. Acad. Sci. USA 110:240-45
94. Yuan J, Cheng KC, Johnson RL, Huang R, Pattaradilokrat S, et al. 2011. Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets. Science 333:724-29
95. Mehlotra RK, Henry-Halldin CN, Zimmerman PA. 2009. Application of pharmacogenomics to malaria: a holistic approach for successful chemotherapy. Pharmacogenomics 10:435-49
96. Dharia NV, Sidhu AB, Cassera MB, Westenberger SJ, Bopp SE, et al. 2009. Use of high-density tiling microarrays to identify mutations globally and elucidate mechanisms of drug resistance in Plasmodium falciparum. Genome Biol. 10:R21
97. Eastman RT, Dharia NV, Winzeler EA, Fidock DA. 2011. Piperaquine resistance is associated with a copy number variation on chromosome 5 in drug-pressured Plasmodium falciparum parasites. Antimicrob. Agents Chemother. 55:3908-16
98. Nam TG, McNamara CW, Bopp S, Dharia NV, Meister S, et al. 2011. A chemical genomic analysis of decoquinate, a Plasmodium falciparum cytochrome b inhibitor. ACS Chem. Biol. 6:1214-22
99. Rottmann M, McNamara C, Yeung BK, Lee MC, Zou B, et al. 2010. Spiroindolones, a potent compound class for the treatment of malaria. Science 329:1175-80
100. Harbut MB, Patel BA, Yeung BK, McNamara CW, Bright AT, et al. 2012. Targeting the ERADpathway via inhibition of signal peptide peptidase for antiparasitic therapeutic design. Proc. Natl. Acad. Sci. USA 109:21486-91
101. Baker N, Alsford S, Horn D. 2011. Genome-wide RNAi screens in African trypanosomes identify the nifurtimox activator NTR and the eflornithine transporter AAT6. Mol. Biochem. Parasitol. 176:55-57
102. Schumann Burkard G, Jutzi P, Roditi I. 2011. Genome-wide RNAi screens in bloodstream form trypanosomes identify drug transporters. Mol. Biochem. Parasitol. 175:91-94
103. Vincent IM, Creek D, Watson DG, Kamleh MA, Woods DJ, et al. 2010. A molecular mechanism for eflornithine resistance in African trypanosomes. PLoS Pathog. 6:e1001204
104. Baker N, Glover L, Munday JC, Aguinaga Andrés D, Barrett MP, et al. 2012. Aquaglyceroporin 2 controls susceptibility to melarsoprol and pentamidine in African trypanosomes. Proc. Natl. Acad. Sci. USA 109:10996-1001
105. Hoepfner D, McNamara CW, Lim CS, Studer C, Riedl R, et al. 2012. Selective and specific inhibition of the Plasmodium falciparum lysyl-tRNA synthetase by the fungal secondary metabolite cladosporin. Cell Host Microbe 11:654-63
106. Maier AG, Rug M, O'Neill MT, Brown M, Chakravorty S, et al. 2008. Exported proteins required for virulence and rigidity of Plasmodium falciparum-infected human erythrocytes. Cell 134:48-61
107. Tewari R, Straschil U, Bateman A, Bohme U, Cherevach I, et al. 2010. The systematic functional analysis of Plasmodium protein kinases identifies essential regulators of mosquito transmission. Cell Host Microbe 8:377-87
108. Dorin-Semblat D, Schmitt S, Semblat JP, Sicard A, Reininger L, et al. 2011. Plasmodium falciparum NIMA-related kinase Pfnek-1: sex specificity and assessment of essentiality for the erythrocytic asexual cycle. Microbiology 157:2785-94
109. Langridge GC, Phan MD, Turner DJ, Perkins TT, Parts L, et al. 2009. Simultaneous assay of every Salmonella Typhi gene using one million transposon mutants. Genome Res. 19:2308-16
110. Murry JP, Rubin EJ. 2005. New genetic approaches shed light on TB virulence. Trends Microbiol. 13:366-72
111. Balu B, Shoue DA, Fraser MJJr, Adams JH. 2005. High-efficiency transformation of Plasmodium falciparum by the lepidopteran transposable element piggyBac. Proc. Natl. Acad. Sci. USA 102:16391-96
112. Ikadai H, Shaw Saliba K, Kanzok SM, McLean KJ, Tanaka TQ, et al. 2013. Transposon mutagenesis identifies genes essential for Plasmodium falciparum gametocytogenesis. Proc. Natl. Acad. Sci. USA 110:1676-84
113. Graves PR, Kwiek JJ, Fadden P, Ray R, Hardeman K, et al. 2002. Discovery of novel targets of quinoline drugs in the human purine binding proteome. Mol. Pharmacol. 62:1364-72
114. Kim HS, Park SH, Gunzl A, Cross GA. 2013. MCM-BP is required for repression of life-cycle specific genes transcribed by RNA polymerase I in the mammalian infectious form of Trypanosoma brucei. PLoS ONE 8:e57001
115. Leal S, Acosta-Serrano A, Morris J, Cross GA. 2004. Transposon mutagenesis of Trypanosoma brucei identifies glycosylation mutants resistant to concanavalin A. J. Biol. Chem. 279:28979-88
116. Judson N, Mekalanos JJ. 2000. Transposon-based approaches to identify essential bacterial genes. Trends Microbiol. 8:521-26
117. Drag M, Salvesen GS. 2010. Emerging principles in protease-based drug discovery. Nat. Rev. Drug Discov. 9:690-701
118. Pan X, Reissman S, Douglas NR, Huang Z, Yuan DS, et al. 2010. Trivalent arsenic inhibits the functions of chaperonin complex. Genetics 186:725-34
119. Alsford S, Eckert S, Baker N, Glover L, Sanchez-Flores A, et al. 2012. High-throughput decoding of antitrypanosomal drug efficacy and resistance. Nature 482:232-36
120. Baker N, de Koning HP, Maser P, Horn D. 2013. Drug resistance in African trypanosomiasis: the melarsoprol and pentamidine story. Trends Parasitol. 29:110-18
121. Alsford S, Field MC, Horn D. 2013. Receptor-mediated endocytosis for drug delivery in African trypanosomes: fulfilling Paul Ehrlich's vision of chemotherapy. Trends Parasitol. 29:207-12
122. Mok S, Imwong M, Mackinnon MJ, Sim J, Ramadoss R, et al. 2011. Artemisinin resistance in Plasmodium falciparum is associated with an altered temporal pattern of transcription. BMC Genomics 12:391
123. Hu G, Cabrera A, Kono M, Mok S, Chaal BK, et al. 2010. Transcriptional profiling of growth perturbations of the human malaria parasite Plasmodium falciparum. Nat. Biotechnol. 28:91-98
124. Siegel TN, Gunasekera K, Cross GA, Ochsenreiter T. 2011. Gene expression in Trypanosoma brucei: lessons from high-throughput RNA sequencing. Trends Parasitol. 27:434-41
125. Ubeda JM, Legare D, Raymond F, Ouameur AA, Boisvert S, et al. 2008. Modulation of gene expression in drug resistant Leishmania is associated with gene amplification, gene deletion and chromosome aneuploidy. Genome Biol. 9:R115
126. Wang K, Yang T, Wu Q, Zhao X, Nice EC, Huang C. 2012. Chemistry-based functional proteomics for drug target deconvolution. Expert Rev. Proteomics 9:293-310
127. Barton V, Ward SA, Chadwick J, Hill A, O'Neill PM. 2010. Rationale design of biotinylated antimalarial endoperoxide carbon centered radical prodrugs for applications in proteomics. J. Med. Chem. 53:4555-59
128. Morita M, Sanai H, Hiramoto A, Sato A, Hiraoka O, et al. 2012. Plasmodium falciparum endoplasmic reticulum-resident calcium binding protein is a possible target of synthetic antimalarial endoperoxides, N-89 and N-251. J. Proteome Res. 11:5704-11
129. Greenbaum DC, Baruch A, Grainger M, Bozdech Z, Medzihradszky KF, et al. 2002. A role for the protease falcipain 1 in host cell invasion by the human malaria parasite. Science 298:2002-6
130. Lucumi E, Darling C, Jo H, Napper AD, Chandramohanadas R, et al. 2010. Discovery of potent small-molecule inhibitors of multidrug-resistant Plasmodium falciparum using a novel miniaturized highthroughput luciferase-based assay. Antimicrob. Agents Chemother. 54:3597-604
131. Harbut MB, Velmourougane G, Dalal S, Reiss G, Whisstock JC, et al. 2011. Bestatin-based chemical biology strategy reveals distinct roles for malaria M1- and M17-family aminopeptidases. Proc. Natl. Acad. Sci. USA 108:E526-34
132. Kuettel S, Mosimann M, Maser P, Kaiser M, Brun R, et al. 2009. Adenosine kinase of T. b. rhodesiense identified as the putative target of 4-[5-(4-phenoxyphenyl)-2H-pyrazol-3-yl]morpholine using chemical proteomics. PLoS Negl. Trop. Dis. 3:e506
133. Mercer L, Bowling T, Perales J, Freeman J, Nguyen T, et al. 2011. 2,4-Diaminopyrimidines as potent inhibitors of Trypanosoma brucei and identification of molecular targets by a chemical proteomics approach. PLoS Negl. Trop. Dis. 5:e956
134. Pieretti S, Haanstra JR, Mazet M, Perozzo R, Bergamini C, et al. 2013. Naphthoquinone derivatives exert their antitrypanosomal activity via a multi-target mechanism. PLoS Negl. Trop. Dis. 7:e2012
135. Urbaniak MD, Mathieson T, Bantscheff M, Eberhard D, Grimaldi R, et al. 2012. Chemical proteomic analysis reveals the drugability of the kinome of Trypanosoma brucei. ACS Chem. Biol. 7:1858-65
136. Creek DJ, Anderson J, McConville MJ, Barrett MP. 2012. Metabolomic analysis of trypanosomatid protozoa. Mol. Biochem. Parasitol. 181:73-84
137. Vincent IM, Creek DJ, Burgess K, Woods DJ, Burchmore RJ, Barrett MP. 2012. Untargeted metabolomics reveals a lack of synergy between nifurtimox and eflornithine against Trypanosoma brucei. PLoS Negl. Trop. Dis. 6:e1618
138. Creek DJ, Nijagal B, Kim DH, Rojas F, Matthews KR, Barrett MP. 2013. Metabolomics guides rational development of a simplified cell culturemedium for drug screening against Trypanosoma brucei. Antimicrob. Agents Chemother. 57:2768-79
139. Olszewski KL, Morrisey JM, Wilinski D, Burns JM, Vaidya AB, et al. 2009. Host-parasite interactions revealed by Plasmodium falciparum metabolomics. Cell Host Microbe 5:191-99
140. Giaever G, Shoemaker DD, Jones TW, Liang H, Winzeler EA, et al. 1999. Genomic profiling of drug sensitivities via induced haploinsufficiency. Nat. Genet. 21:278-83
141. Ranade RM, Gillespie JR, Shibata S, Verlinde CLMJ, Fan E, et al. 2013. Induced resistance to methionyltRNA synthetase inhibitors in Trypanosoma brucei is due to overexpression of the target. Antimicrob. Agents Chemother. 57:3021-28
142. Armstrong CM, Goldberg DE. 2007. An FKBP destabilization domain modulates protein levels in Plasmodium falciparum. Nat. Methods 4:1007-9
143. Collins CR, Das S, Wong EH, Andenmatten N, Stallmach R, et al. 2013. Robust inducible Cre recombinase activity in the humanmalaria parasite Plasmodium falciparum enables efficient gene deletion within a single asexual erythrocytic growth cycle. Mol. Microbiol. 88:687-701
144. Straimer J, Lee MC, Lee AH, Zeitler B, Williams AE, et al. 2012. Site-specific genome editing in Plasmodium falciparum using engineered zinc-finger nucleases. Nat. Methods 9:993-98
145. Farrell A, Thirugnanam S, Lorestani A, Dvorin JD, Eidell KP, et al. 2012. A DOC2 protein identified by mutational profiling is essential for apicomplexan parasite exocytosis. Science 335:218-21
146. Dos Santos SC, Sa-Correia I. 2011. A genome-wide screen identifies yeast genes required for protection against or enhanced cytotoxicity of the antimalarial drug quinine. Mol. Genet. Genomics 286:333-46
147. Lye LF, Owens K, Shi H, Murta SM, Vieira AC, et al. 2010. Retention and loss of RNA interference pathways in trypanosomatid protozoans. PLoS Pathog. 6:e1001161
148. De Rycker M, O'Neill S, Joshi D, Campbell L, Gray DW, Fairlamb AH. 2012. A static-cidal assay for Trypanosoma brucei to aid hit prioritisation for progression into drug discovery programmes. PLoS Negl. Trop. Dis. 6:e1932
149. Raju RM, Goldberg AL, Rubin EJ. 2012. Bacterial proteolytic complexes as therapeutic targets. Nat. Rev. Drug Discov. 11:777-89
150. Roemer T, Boone C. 2013. Systems-level antimicrobial drug and drug synergy discovery. Nat. Chem. Biol. 9:222-31
151. Jiang L, Mu J, Zhang Q, Ni T, Srinivasan P, et al. 2013. PfSETvs methylation of histone H3K36 represses virulence genes in Plasmodium falciparum. Nature 499:223-27
152. Chandramohanadas R, Davis PH, Beiting DP, Harbut MB, Darling C, et al. 2009. Apicomplexan parasites co-opt host calpains to facilitate their escape from infected cells. Science 324:794-97
153. Harrison T, Samuel BU, Akompong T, Hamm H, Mohandas N, et al. 2003. Erythrocyte G protein-coupled receptor signaling in malarial infection. Science 301:1734-36
154. Murphy SC, Harrison T, Hamm HE, Lomasney JW, Mohandas N, Haldar K. 2006. Erythrocyte G protein as a novel target for malarial chemotherapy. PLoS Med. 3:e528
155. Bei AK, Brugnara C, Duraisingh MT. 2010. In vitro genetic analysis of an erythrocyte determinant of malaria infection. J. Infect. Dis. 202:1722-27
156. Prudencio M, Mota MM. 2013. Targeting host factors to circumvent anti-malarial drug resistance. Curr. Pharm. Des. 19:290-99
157. Wyllie S, Patterson S, Stojanovski L, Simeons FR, Norval S, et al. 2012. The anti-trypanosome drug fexinidazole shows potential for treating visceral leishmaniasis. Sci. Transl. Med. 4:119re1
158. Huang Z, Chen K, Zhang J, Li Y, Wang H, et al. 2013. A functional variomics tool for discovering drug-resistance genes and drug targets. Cell Rep. 3:577-85